OBJECTIVE: The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effective therapeutic strategy for individuals suffering from massive hepatocellular carcinoma.
MATERIALS AND METHODS: A retrospective analysis was conducted using clinical data from 118 patients with unresectable massive hepatocellular carcinoma who underwent treatment at the Interventional Department of Wuhan Union Hospital between June 2018 and December 2021. Based on the treatment approach, the patients were divided into two groups: the D-TACE + HAIC + Lenvatinib group (N = 54) and the D-TACE + Lenvatinib group (N = 64). The primary study endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) of the two groups. Additionally, the occurrence of treatment-related adverse events in both groups was considered as a secondary study endpoint.
RESULTS: Following the treatment, the D-TACE + HAIC + Lenvatinib group exhibited significantly higher ORR and DCR compared to the D-TACE + Lenvatinib group (68.5% vs. 43.8%, 90.7% vs. 73.4%, P < 0.05). Moreover, the D-TACE + HAIC + Lenvatinib group demonstrated longer mPFS and mOS in comparison to the D-TACE + Lenvatinib group (8.6 months vs. 6.6 months, P = 0.005; 19.5 months vs. 14.1 months, P < 0.001). There was no statistically significant difference in the occurrence rate of common treatment-related adverse events between the TACE + HAIC + Lenvatinib group and the D-TACE + Lenvatinib group (P > 0.05).
CONCLUSION: The combined treatment regimen of D-TACE, HAIC, and Lenvatinib demonstrated superior therapeutic efficacy and safety in managing unresectable massive hepatocellular carcinoma. This combination therapy may serve as a viable option for improving the prognosis of patients with unresectable massive hepatocellular carcinoma.
Clin Liver Dis. 2023 Feb;27(1):85-102
[PMID:
36400469]
Aliment Pharmacol Ther. 2006 Jan 1;23(1):129-35
[PMID:
16393290]
World J Gastroenterol. 2004 Oct 1;10(19):2878-82
[PMID:
15334691]
Dig Dis. 2009;27(2):157-63
[PMID:
19546554]
Eur J Cancer. 2020 Jul;134:90-98
[PMID:
32497895]
Medicine (Baltimore). 2022 Dec 23;101(51):e32390
[PMID:
36595819]
J Surg Oncol. 2022 Dec;126(7):1205-1214
[PMID:
35856502]
HPB (Oxford). 2015 Jul;17(7):611-23
[PMID:
25980326]
Curr Cancer Drug Targets. 2023;23(7):564-571
[PMID:
36790005]
J Clin Oncol. 2023 Jan 1;41(1):117-127
[PMID:
35921605]
Radiol Oncol. 2023 Feb 17;57(1):70-79
[PMID:
36794998]
Am J Gastroenterol. 2008 Apr;103(4):914-21
[PMID:
18177453]
Eur J Gastroenterol Hepatol. 2011 Jun;23(6):521-7
[PMID:
21537127]
Future Oncol. 2018 Dec;14(28):2957-2967
[PMID:
29712486]
J Exp Clin Cancer Res. 2010 Dec 15;29:164
[PMID:
21159184]
World J Gastroenterol. 2015 Sep 28;21(36):10327-35
[PMID:
26420959]
Clin Transl Gastroenterol. 2017 Jun 15;8(6):e98
[PMID:
28617447]
Acad Radiol. 2021 Nov;28 Suppl 1:S157-S166
[PMID:
33653656]
Front Oncol. 2022 Jan 21;11:793581
[PMID:
35127501]
Cureus. 2023 Jul 16;15(7):e41943
[PMID:
37465089]
J Cancer Res Ther. 2021 Jul;17(3):733-739
[PMID:
34269307]
HPB (Oxford). 2017 Aug;19(8):659-666
[PMID:
28552299]
CA Cancer J Clin. 2021 May;71(3):209-249
[PMID:
33538338]
Zhonghua Yi Xue Za Zhi. 2023 Sep 12;103(34):2674-2694
[PMID:
37675541]
World J Gastroenterol. 2018 Jun 21;24(23):2501-2507
[PMID:
29930471]
Front Public Health. 2022 Oct 26;10:963058
[PMID:
36388345]
Pharmaceuticals (Basel). 2021 Jan 06;14(1):
[PMID:
33418941]
Semin Liver Dis. 2010 Feb;30(1):61-74
[PMID:
20175034]
Cancers (Basel). 2022 Aug 20;14(16):
[PMID:
36011021]
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):674-681
[PMID:
34866846]
Anticancer Drugs. 2016 Aug;27(7):689-94
[PMID:
27145327]
Hepatol Res. 2019 Jul;49(7):787-798
[PMID:
30907468]
J Hepatocell Carcinoma. 2022 Aug 01;9:685-694
[PMID:
35937909]
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101851
[PMID:
34923180]
Indian J Cancer. 2015 Feb;51 Suppl 2:e49-51
[PMID:
25712844]
Semin Liver Dis. 2010 Feb;30(1):52-60
[PMID:
20175033]
Hepatogastroenterology. 2012 May;59(115):820-5
[PMID:
22024228]
Chemotherapy. 2021;66(4):124-133
[PMID:
34515082]
J Hepatocell Carcinoma. 2021 Nov 26;8:1445-1458
[PMID:
34858889]
Eur J Gastroenterol Hepatol. 2014 Jan;26(1):101-8
[PMID:
23863262]
Front Pharmacol. 2022 Oct 21;13:965770
[PMID:
36339553]
Oncology. 2021;99(8):507-517
[PMID:
33946070]
Actas Dermosifiliogr (Engl Ed). 2021 Jan;112(1):90-92
[PMID:
32891586]
Biochem Biophys Res Commun. 2019 May 21;513(1):1-7
[PMID:
30944079]
Hepatol Int. 2021 Jun;15(3):663-675
[PMID:
33877527]
Surg Oncol Clin N Am. 2014 Apr;23(2):289-311
[PMID:
24560111]
J Clin Oncol. 2022 Jan 10;40(2):150-160
[PMID:
34648352]
Front Bioeng Biotechnol. 2022 Sep 27;10:1010824
[PMID:
36237208]
J Gastrointestin Liver Dis. 2022 Sep 15;31(3):336-343
[PMID:
36112704]
J Clin Oncol. 2022 Feb 10;40(5):468-480
[PMID:
34905388]
J Gastrointest Cancer. 2020 Mar;51(1):250-253
[PMID:
31054105]
Adv Cancer Res. 2021;149:1-61
[PMID:
33579421]
Ir J Med Sci. 2022 Dec;191(6):2493-2499
[PMID:
35064533]
Int J Mol Sci. 2021 Nov 28;22(23):
[PMID:
34884684]
Med Oncol. 2015 Mar;32(3):64
[PMID:
25682389]
Future Oncol. 2018 Dec;14(28):2969-2984
[PMID:
29987957]
J Interv Med. 2019 Jul 31;2(2):91-96
[PMID:
34805879]
Int J Mol Sci. 2020 Oct 31;21(21):
[PMID:
33142892]
World J Surg Oncol. 2023 Mar 31;21(1):120
[PMID:
37004052]
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1295-1307
[PMID:
34624198]
J Clin Oncol. 2023 Apr 1;41(10):1898-1908
[PMID:
36525610]
J Gastroenterol. 2020 Jan;55(1):113-122
[PMID:
31720835]
Jpn J Radiol. 2019 Jul;37(7):543-548
[PMID:
31055710]
Cancers (Basel). 2022 Jul 29;14(15):
[PMID:
35954373]
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188391
[PMID:
32659252]
